Pomalidomidefeatured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:202310
CAS#:19171-19-8
Description:Pomalidomide, also known as CC4047, is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). Pomalidomide was approved on February 8, 2013 as a treatment for relapsed and refractory multiple myeloma.
Price and Availability
Pomalidomide, purity > 98%, is in stock. The same day shipping out after order is received.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 202310Name: PomalidomideCAS#: 19171-19-8Chemical Formula: C13H11N3O4Exact Mass: 273.07496Molecular Weight: 273.24Elemental Analysis:C, 57.14; H, 4.06; N, 15.38; O, 23.42
Synonym:CC4047; CC 4047; CC-4047; Pomalidomide. Brand name: Pomalyst.
IUPAC/Chemical Name:4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
InChi Key:UVSMNLNDYGZFPF-UHFFFAOYSA-N
InChi Code:InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
SMILES Code:O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3N)=O
Technical Data
References
1: Elkinson S, McCormack PL. Pomalidomide: FirstGlobal Approval. Drugs. 2013 Apr 10. [Epub ahead of print] PubMed PMID:23572409.
2: Traynor K. Pomalidomide approved for multiple myeloma. Am J HealthSyst Pharm. 2013 Mar 15;70(6):474. doi: 10.2146/news130020. PubMed PMID:23456394.
3: Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, GalustianC. Enhanced cross-priming of naive CD8+ T cells by DCs treated by theIMiDs(®) immunomodulatory compounds Lenalidomide and Pomalidomide.Immunology. 2013 Feb 1. doi: 10.1111/imm.12087. [Epub ahead of print]PubMed PMID: 23374145.
4: Ellis PM, Jungnelius U, Zhang J, Fandi A, Beck R, Shepherd FA. APhase I Study of Pomalidomide (CC-4047) in Combination with Cisplatinand Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer. JThorac Oncol. 2013 Apr;8(4):423-8. doi: 10.1097/JTO.0b013e318282707b.PubMed PMID: 23370364.
5: Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C,Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, HennacheB, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C,Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D,Fermand JP, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome.Pomalidomide plus low-dose dexamethasone is active and well tolerated inbortezomib and lenalidomide-refractory multiple myeloma: IntergroupeFrancophone du Myelome 2009-02. Blood. 2013 Mar 14;121(11):1968-75. doi:10.1182/blood-2012-09-452375. Epub 2013 Jan 14. PubMed PMID: 23319574.
6: Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J,Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N,McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M,Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD,safety, and efficacy in patients with refractory multiple myeloma whohave received lenalidomide and bortezomib. Blood. 2013 Mar14;121(11):1961-7. doi: 10.1182/blood-2012-08-450742. Epub 2012 Dec 14.PubMed PMID: 23243282.
7: Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, PartonA, Kim-Kang H, Surapaneni S, Kumar G. Absorption, metabolism andexcretion of [14C]pomalidomide in humans following oral administration.Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. doi:10.1007/s00280-012-2040-6. Epub 2012 Dec 1. PubMed PMID: 23203815;PubMed Central PMCID: PMC3556473.
8: Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D,Agnelli L, Neri A, Rizzoli V, Giuliani N. Immunomodulatory drugslenalidomide and pomalidomide inhibit multiple myeloma-inducedosteoclast formation and the RANKL/OPG ratio in the myelomamicroenvironment targeting the expression of adhesion molecules. ExpHematol. 2012 Nov 23. doi:pii: S0301-472X(12)00542-5.10.1016/j.exphem.2012.11.005. [Epub ahead of print] PubMed PMID:23178378.
9: Ruchelman AL, Man HW, Zhang W, Chen R, Capone L, Kang J, Parton A,Corral L, Schafer PH, Babusis D, Moghaddam MF, Tang Y, Shirley MA,Muller GW. Isosteric analogs of lenalidomide and pomalidomide: synthesisand biological activity. Bioorg Med Chem Lett. 2013 Jan 1;23(1):360-5.doi: 10.1016/j.bmcl.2012.10.071. Epub 2012 Oct 27. PubMed PMID:23168019.
10: Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action ofimmune-modulatory drugs thalidomide, lenalidomide and pomalidomide inmultiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. doi:10.3109/10428194.2012.728597. Epub 2012 Sep 28. PubMed PMID: 22966948.
我国旅美科学家陈清奇博士创立的MedKoo美帝药库医药公司目前正在建立全球第一个小分子抗癌药库。 MedKoo是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司。 业务范围 为全球所有从事抗癌药物研究和开发的制药公司，高校，研究院所，政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。 技术核心 以药物化学合成技术为核心，密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向，不断推出抗癌化合物新品种。 建造目标 MedKoo美帝药库的目标是：建成全球最大的小分子抗癌药库 ，品种最多最全、质量最好最可靠。美帝药库的宗旨是：客户第一；质量第一；信誉第一；创新第一。
